Business Context and Reporting Period
Company: Microbot Medical Inc. (MBOT)
Filing Type: Form 8-K (Current Report)
Date of Report: June 23, 2026
Principal Office: Hingham, MA
This filing reports a strategic commercial milestone regarding the adoption of the Company's LIBERTY® Endovascular Robotic System.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes and Events
- New Adoption: A globally recognized academic center in Pennsylvania has become the first in that state to adopt the LIBERTY® Endovascular Robotic System.
- Geographic Expansion: The Company now maintains accounts in seven states across the Eastern United States.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains statements regarding future beliefs, plans, expectations, and regulatory milestones. Management notes that actual results may differ due to numerous factors.
Risks: Investors are directed to consult risk factors disclosed in other SEC filings. The Company assumes no obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the identity of the Pennsylvania academic center and the specific terms of the adoption agreement.
- Confirm the total number of active accounts in the Eastern U.S. and the revenue contribution from these seven states.
- Review the Company's most recent 10-K or 10-Q for detailed financial health and liquidity status, as this 8-K does not contain such data.
- Assess the timeline for regulatory milestones mentioned in the forward-looking statements.